Nasdaq:US$15.41 (+0.36) | HKEX:HK$23.55 (-0.20) | AIM:£2.23 (-0.04)
Search Result
Previous Article   |   Next Article
Announcements & Press Releases, Oncology / Immunology | 29 Feb 2008

Chi-Med Announces Start of Patient Enrolment in a Global Phase IIb Ulcerative Colitis Clinical Trial of HMPL-004, its Leading Anti-Inflammatory Drug Candidate

1 items
a080229